Navigation Links
PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting
Date:3/16/2009

ion with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2008 as filed with the SEC on February 9, 2009, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

    Contacts:
    Jennifer Baird, Senior Director of Public Relations
    PAREXEL International
    Tel: +781-434-4409
    Email: Jennifer.Baird@PAREXEL.com

    Rebecca Passo
    SHIFT Communications
    Tel: +617-779-1817
    Email: rpasso@shiftcomm.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009
2. PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting
3. PAREXEL Appoints Josephine Hoppe to Chief Information Officer
4. PAREXEL International to Present at the 27th Annual JP Morgan Healthcare Conference
5. PAREXEL Receives Best CRO Award from Scrip
6. PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies
7. PAREXEL Expands Pioneering Asian Ethnobridging Expertise
8. PAREXEL Expert to Address Key Aspects of Conducting Clinical Trials in China at 7th Annual Partnerships in Clinical Trials Congress
9. PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference
10. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
11. PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...Reportlinker.comannouncesthatanewmarketresearchrep...nolMarketAnalysisandForecaststo2013 ,, http:/...arket-Analysis-and-Forecasts-to-2013.html ,, B..., Summary ,, Thereportprovidesdetailedanaly...azilbioethanolmarketinparticular.Italsohelpsinanal...
(Date:11/24/2009)...rstCall/--IES(Nasdaq: IESC ),aleadingnationalprovi...forthecommercial,industrialandresidentialmarkets,a...awardedacontractfromManhattanTorconJVtoinstallthee...placementfacilityattheU.S.ArmyMedicalResearchInsti...rederick,Md. ,, ThenewUSAMRIIDreplacementfacili...
(Date:11/24/2009)...wswire/--TwomoreprestigiousuniversitieshavejoinedB...careerssiteforlifescienceprofessionals. ,, Nort...board,joining28othermajorlifesciencetrainingInstit... ,isonlyforpost-graduatesinthelifesciences.Whileth...t,BioCareerCenteristheonlyonethatserveslifescience...
(Date:11/24/2009)...irstCall/--Sigma-AldrichCorporation(Nasdaq: SIAL )...December1stat1:45PMGMTinLondon,7:45AMUS/CST.Intere...ternetavailableat http://inve s tor.sig m a ...cessthisfile. ,, AboutSigma-Aldrich: Sigma-A...y.Itschemicalandbiochemicalproductsandkitsareusedi...
Breaking Biology Technology:Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2
... SBIR Grant Funding to Advance the Development of ... RNAi Drugs, CARLSBAD, Calif., Oct. 3 Isis,Pharm...that it has been,awarded a multi-year Phase 2 Smal... National Institutes of Health (NIH) for up to $1.... exploit the RNA interference (RNAi),antisense mec...
...T LAFAYETTE, Ind. - Engineers have shown how to gr...es onto the surfaces of computer chips to enhance ...ps connect to cooling devices called heat sinks. ,...n to outperform conventional "thermal interface ma... does not require elaborate clean-room environment...
...A, Calif., Oct. 2 MannKind Corporation,(Nasdaq: ...a total of,27,014,686 shares of its common stock i...ts principal stockholder, Chief Executive Officer ... groups of investors,including accounts managed by...d shares, 15,940,489 shares were sold to Mr. Mann ...
Other Biology Technology:Isis Awarded $1.5 Million NIH Grant to Improve Chemical Properties of RNAi-Based Therapeutics 2Isis Awarded $1.5 Million NIH Grant to Improve Chemical Properties of RNAi-Based Therapeutics 3Nanotube forests grown on silicon chips for future computers, electronics 2Nanotube forests grown on silicon chips for future computers, electronics 3MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock 2MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock 3
(Date:11/23/2009)...TINew research presents strong evidence that the "... outdoor traffic-related pollution and indoor endo...e or the other exposure alone. , Environmental... (UC) College of Medicine have shown that children...rticles and indoor endotoxin during early life are...
(Date:11/23/2009)...O, November 23, 2009 - The time of day matters to ...new paper produced by a research team led by Profe...orough,s vice-principal for research and colleague... the St. George campus. , Capitalizing on thei... tree, the research team examined how poplar trees...
(Date:11/23/2009)...on, CT Current research suggests that a common or...he related report by Nichols et al, "Unique Lipids...ss of TLR2 Ligands Capable of Enhancing Autoimmuni...erican Journal of Pathology . , Multiple scleros... the brain and spinal cord, affects nearly 1 in 70...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Time of day matters to thirsty trees, U of T researcher discovers 2Factors from common human bacteria may trigger multiple sclerosis 2Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 1Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 2Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 3Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 4Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 5Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 6Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 7Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 8Tamoxifen May Up Risk of Second More Aggressive Breast Cancer 55316 1Tamoxifen May Up Risk of Second More Aggressive Breast Cancer 55316 2SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 13688 1SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 13688 2SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 13688 3SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 13688 4
...mmonwealth University Massey Cancer Center have id...ible new therapeutic target to improve the efficac...In the Nov. 1 issue of the journal Cancer Research...er cells and established a role of sphingosine kin...id mediator sphingosine-1-phosphate in the death o...
...the world is still plagued by diseases we cannot t...ast complexity of the human immune system. Danish ... help expose a complicated but crucial part of the...an lead to entirely new vaccines and treatments. ... of Health Sciences at the University of Copenhage...
...can contribute as much as vehicles to carbon emiss...hly variable. New research published in the online... quantifies these emissions and suggests fires wil...forts. , Christine Wiedinmyer of the National Cen... University of Colorado, both in Boulder, US, used...
Other Biology News:Potential new therapeutic molecular target to fight cancer 2US faces burning emissions issue 2
Mouse Anti-DNA-PKcs, phospho (Thr2609) Monoclonal Antibody, Unconjugated, Clone 10B1 from BioLegend
Rabbit Anti-Histamine H2 Receptor Polyclonal Antibody, Unconjugated from IMGENEX
NF kappa B Related Sampler Kit from BD Biosciences Pharmingen
Glycogen Coprecipitant from Bioline
Biology Products: